timothy sykes logo

Stock News

Terns Pharmaceuticals’ Path: A Stock to Watch?

Tim SykesAvatar
Written by Timothy Sykes Reviewed by Bryce Tuohey Fact-checked by Matt Monaco
Updated 12/8/2025, 5:05 pm ET 12/8/2025, 5:05 pm ET | 5 min 5 min read
Terns Pharmaceuticals’ Path: A Stock to Watch? Thumbnail

Terns Pharmaceuticals Inc. stocks have been trading up by 36.14 percent after promising clinical trials boosted investor confidence.

  • After reviewing TERN-701’s performance in chronic myeloid leukemia, Truist adjusted Terns Pharmaceuticals’ target price to $35, while maintaining a Buy rating.

  • Citizens JMP upped Terns Pharmaceuticals’ target price from $25 to $35, highlighting the exceptional findings from TERN-701’s testing for relapsed/refractory conditions, which were notably more effective than other Phase 1 therapies.

  • Driven by TERN-701’s recent findings in chronic myeloid leukemia, BMO Capital revised the target price to $30, recognizing its clear differentiation from existing treatments.

  • Mizuho raised Terns Pharmaceuticals’ price target to $33, reinforced by the positive reactions following the Q3 earnings report.

Candlestick Chart

Live Update At 17:04:35 EST: On Monday, December 08, 2025 Terns Pharmaceuticals Inc. stock [NASDAQ: TERN] is trending up by 36.14%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Performance & Analysis

As traders, it’s crucial to approach the market with a disciplined mindset. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” This principle is vital for achieving long-term success. When the right opportunity arises, your preparedness and patience will pay off, but you must avoid impulsive decisions driven by emotions. Remember, in trading, patience is not just a virtue; it’s an essential part of your strategy.

Terns Pharmaceuticals has seen considerable shifts recently, with analyst predictions shedding light on potential moves. The financial landscape includes both optimistic targets from analysts and crucial market responses. With price targets shifting from slightly over $27 to hitting the $36 mark recently, Terns Pharmaceuticals seems to be on a promising trajectory. Investors have shown heightened interest after positive data releases regarding TERN-701. It’s notable how the company has continued to captivate investors with growing confidence in their chronic myeloid leukemia trials.

Digging deeper into their recent financials, Terns Pharmaceuticals reported a Q3 EPS (Earnings Per Share) of (27c), surpassing forecasts set at (30c). This better-than-expected performance has bolstered confidence in their strategies. Simultaneously, important standout moments came from their CARDINAL program, illustrating an impressive Phase 1 milestone response rate and a encouraging safety profile for TERN-701.

However, their income statements illustrate a loss of $24.6M, mainly attributed to extensive research expenses, which, although significant, align with the narrative of a company in rapid developmental phases. Their cash flows see a dip, though investments have highlighted the company’s drive to ensure future growth and development.

News Impact & Implications

The trajectory of Terns Pharmaceuticals has been molded by several factors. Analysts see the potential giant strides TERN-701 could make in the chronic myeloid leukemia sector, a vital turning point for the company. Barclays and other analysts’ upward revision of the price target reflect a shared sentiment of robust potential and an inclination towards believing in its future success.

Egos aligned in raising the price target points toward a consensus about Terns Pharmaceuticals’ potential. Their transition towards a patient-based framework for TERN-701 could redefine their role in the chronic myeloid leukemia domain.

Moreover, the market’s response can be partly attributed to the firm’s strategic decisions and technology-driven advancements. While the company’s financials come under scrutiny, especially their net income and cash flows, the prevailing faith in market predictions offers a place for optimism.

More Breaking News

Conclusion and Outlook

Although the recent quarter highlights some financial challenges, the company’s targeted development approach provides a cushion of hope for future gains. Terns Pharmaceuticals’ groundwork in chronic myeloid leukemia significantly shifts its trajectory, preparing it for expansive market entry. There’s anticipation around how their current strategies will manifest in consistent long-term growth.

The overarching question remains: Will these strategies propel Terns Pharmaceuticals into a strong market stance, capitalizing on its recent innovations? Judging by the current market chatter and insightful price revisions, the journey appears bright. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” This advice resonates well with market dynamics, particularly as Terns Pharmaceuticals rides on the back of analyst confidence and the potential ground-breaking transformation of their ongoing trials. In conclusion, keeping an eye on Terns Pharmaceuticals as they navigate through these strategic waters could provide valuable insights into their forthcoming market performance.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Tim Sykes

Head Writer at TimothySykes.com, Lead Mentor at the Trading Challenge
In his 20-plus years of trading, Tim has made $7.9 million. In his 15-plus years of teaching, Tim’s Trading Challenge has produced over 30 millionaire students. His philosophy emphasizes small gains and cutting losses quickly.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”